Active Biotech AB Interim report January-June 2014

Laquinimod

On May 23, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) reaffirmed its negative opinion on the market application for laquinimod (Nerventra®)CHMP confirmed that the risks observed in animal studies do not prevent a registration for treatment in humansThe ongoing US pivotal clinical study CONCERTO is continuing according to plan. The results are expected in 2016

Tasquinimod     

The Phase III study 10TASQ10 is proceeding according to plan

ANYARA

Development program for further clinical development outlined in collaboration with regulatory authoritiesAll project activities will be put on hold until further notice

                 
Paquinimod (57-57)  

In June 2014, data related to the drug candidate paquinimod for the treatment of systemic sclerosis was presented at the scientific conference "EULAR Annual European Congress of Rheumatology"

ISI

Expansion of the patent portfolioCD selection expected in 2015

Financial summary

MSEK April - JuneJanuary - JuneFull Year 2014 2013 2014 2013 2013          Net sales 2.7 2.5   4.9 5.0   116.0 Operating loss -57.9 -79.5   -117.2 -156.5   -209.0 Loss for the period -57.7 -81.2   -117.9 -159.2   -212.1 Loss per share (SEK) -0.77 -1.08   -1.57 -2.18   -2.87

For further information, please contact:

Tomas Leanderson, President and CEO
 Tel: +46 (0)46 19 20 95
  
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44 Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

The report is also available at www.activebiotech.comActive Biotech AB Interim report January-June 2014


This announcement is distributed by Nasdaq OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire
HUG#1846988